European Companies Search Engine
EU funding (€1,493,420): Advancing scientific collaboration in phage therapy for treating Pseudomonas aeruginosa and Staphylococcus aureus Hor3 Jun 2024 EU Research and Innovation programme "Horizon"
Text
Advancing scientific collaboration in phage therapy for treating Pseudomonas aeruginosa and Staphylococcus aureus
ASCLEPIUS’s overall aim is to boost the scientific excellence and innovation capacity of Giorgi Eliava Institute of Bacteriophagy, Microbiology and Virology (Eliava) and its high-quality Twinning partners - l’Institut national de recherche pour l’agriculture, l’alimentation et l’environnement, Universidade do Minho and Intelligentsia Consultants Sarl – to expand their insights in phage therapy for treating Pseudomonas aeruginosa and Staphylococcus aureus. To achieve this aim, ASCLEPIUS will implement a research and innovation strategy over three years based upon five objectives: Objective 1: Conduct exploratory research on phage therapy for treating Pseudomonas aeruginosa and Staphylococcus aureus. Objective 2: Transfer knowledge between experienced researchers of Eliava and the Twinning partners. Objective 3: Enhance career prospects of early-stage researchers of Eliava and the Twinning partners. Objective 4: Improve Eliava’s management and administrative capacity for European R&D programmes. Objective 5: Raise the research profile of Eliava and the Twinning partners.
Funded Companies:
| Company name | Funding amount |
| Giorgi Eliava Institute OF Bacteriophagy, Microbiology AND Virology | €600,875 |
| Institut National de Recherche Pour l'Agriculture, l'Alimentation et l'Environnement | €454,420 |
| Intelligentsia Consultants Sàrl | €145,250 |
| Universidade do Minho | €292,875 |
Source: https://cordis.europa.eu/project/id/101159555
The filing refers to a past date, and does not necessarily reflect the current state.
The visualizations for "Giorgi Eliava Institute OF Bacteriophagy, Microbiology AND Virology - EU funding (€1,493,420): Advancing scientific collaboration in phage therapy for treating Pseudomonas aeruginosa and Staphylococcus aureus"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
